Interleukin-28B genotyping by melt-mismatch amplification mutation assay PCR analysis using single nucleotide polymorphisms rs12979860 and rs8099917, a useful tool for prediction of therapy response in hepatitis C patients

Journal of Clinical Microbiology

Volumn 49, Issue 7, 2011, Pages 2706-2710

  Fonseca Coronado, Salvador ^a   Vaughan, Gilberto ^b   Cruz Rivera, Mayra Yolanda ^c   Carpio Pedroza, Juan Carlos ^b   Ruiz Tovar, Karina ^b   Ruiz Pacheco, Juan Alberto ^b   Escobar Gutiérrez, Alejandro ^b  

^a UNIVERSIDAD NACIONAL AUTÓNOMA DE MÉXICO   (Mexico)

^b Instituto Nacional de Diagnostico y Referencia Epidemiologicos   (Mexico)

^c UNIVERSIDAD NACIONAL AUTÓNOMA DE MÉXICO   (Mexico)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIVIRUS AGENT; INTERLEUKIN 28B;

ADULT; AGED; ALLELE; ARTICLE; CLINICAL ARTICLE; CLINICAL PROTOCOL; CONTROLLED STUDY; FEMALE; FOLLOW UP; GENE; GENOTYPE; HEPATITIS C; HETEROZYGOSITY; HOMOZYGOSITY; HUMAN; IL 28B GENE; MALE; MELT MISMATCH AMPLIFICATION MUTATION ASSAY; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; SENSITIVITY AND SPECIFICITY; SINGLE NUCLEOTIDE POLYMORPHISM;

AGED; ANTIVIRAL AGENTS; FEMALE; GENOTYPE; HEPATITIS C, CHRONIC; HUMANS; INTERLEUKINS; MALE; MIDDLE AGED; MUTATION; POLYMERASE CHAIN REACTION; POLYMORPHISM, SINGLE NUCLEOTIDE; PROGNOSIS; TRANSITION TEMPERATURE; TREATMENT OUTCOME;

HEPATITIS C VIRUS;

EID: 79959847561     PISSN: 00951137     EISSN: 1098660X     Source Type: Journal    
DOI: 10.1128/JCM.00877-11     Document Type: Article

References (22)

1. Akuta, N., et al. 2009. A matched case-controlled study of 48 and 72 weeks of peginterferon plus ribavirin combination therapy in patients infected with HCV genotype 1b in Japan: amino acid substitutions in HCV core region as predictor of sustained virological response. J. Med. Virol. 81:452-458.
2. Alavian, S. M., B. Behnava, and S. V. Tabatabaei. 2010. Comparative efficacy and overall safety of different doses of consensus interferon for treatment of chronic HCV infection: a systematic review and meta-analysis. Eur. J. Clin. Pharmacol. 66:1071-1079.
3. Alonso, R., et al. 2005. MAMA-PCR assay for the detection of point mutations associated with high-level erythromycin resistance in Campylobacter jejuni and Campylobacter coli strains. J. Microbiol. Methods 63:99-103. (Pubitemid 41266891)
4. Alter, M. J. 2007. Epidemiology of hepatitis C virus infection. World J. Gastroenterol. 13:2436-2441.
5. Aurora, R., M. J. Donlin, N. A. Cannon, and J. E. Tavis. 2009. Genome-wide hepatitis C virus amino acid covariance networks can predict response to antiviral therapy in humans. J. Clin. Invest. 119:225-236.
6. Donlin, M. J., et al. 2010. Contribution of genome-wide HCV genetic differences to outcome of interferon-based therapy in Caucasian American and African American patients. PLoS One 5:e9032.
7. Ferlay, J., et al. 2010. GLOBOCAN 2008, cancer incidence and mortality worldwide: IARC CancerBase no. 10. International Agency for Research on Cancer, Lyon, France. http://globocan.iarc.fr/.
8. Ge, D., et al. 2009. Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature 461:399-401.
9. Global Burden of Hepatitis C Working Group. 2004. Global burden of disease (GBD) for hepatitis C. J. Clin. Pharmacol. 44:20-29.
10. Hoofnagle, J. H., A. S. Wahed, R. S. Brown, Jr., C. D. Howell, and S. H. Belle. 2009. Early changes in hepatitis C virus (HCV) levels in response to peginterferon and ribavirin treatment in patients with chronic HCV genotype 1 infection. J. Infect. Dis. 199:1112-1120.
11. Jinneman, K. C., and W. E. Hill. 2001. Listeria monocytogenes lineage group classification by MAMA-PCR of the listeriolysin gene. Curr. Microbiol. 43:129-133.
12. Lemon, S. M., C. M. Walker, M. J. Alter, and M. Yi. 2007. Hepatitis C virus, p. 1253-1304. In D. M. Knipe and P. M. Howley (ed.), Fields virology, vol. 1. Lippincott Williams & Wilkins, Philadelphia, PA.
13. Li, B., I. Kodura, D. J. Fu, and D. E. Watson. 2004. Genotyping with Taq MAMA. Genomics 83:311-320.
14. Papp, A. C., J. K. Pinsonneault, G. Cooke, and W. Sadee. 2003. Single nucleotide polymorphism genotyping using allele-specific PCR and fluorescence melting curves. Biotechniques 34:1068-1072. (Pubitemid 36554575)
15. Rauch, A., et al. 2010. Genetic variation in IL28B is associated with chronic hepatitis C and treatment failure: a genome-wide association study. Gastroenterology 138:1338-1345, 1345 e1-e7.
16. Rodriguez-Castillo, A., G. Vaughan, J. E. Ramirez-Gonzalez, and A. Escobar-Gutierrez. 2010. Simultaneous cocirculation of both European varicellazoster virus genotypes (E1 and E2) in Mexico City. J. Clin. Microbiol. 48:1712-1715.
17. Saludes, V., et al. 2010. Baseline prediction of combination therapy outcome in hepatitis C virus 1b infected patients by discriminant analysis using viral and host factors. PLoS One 5:e14132.
18. Seeff, L. B. 2002. Natural history of chronic hepatitis C. Hepatology 36:S35-S46. (Pubitemid 35253462)
19. Suppiah, V., et al. 2009. IL28B is associated with response to chronic hepatitis C interferon-alpha and ribavirin therapy. Nat. Genet. 41:1100-1104.
20. Tanaka, Y., et al. 2009. Genome-wide association of IL28B with response to pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C. Nat. Genet. 41:1105-1109.
21. Teoh, N. C., G. C. Farrell, and H. L. Chan. 2010. Individualisation of antiviral therapy for chronic hepatitis C. J. Gastroenterol. Hepatol. 25:1206-1216.
22. Thomas, D. L., et al. 2009. Genetic variation in IL28B and spontaneous clearance of hepatitis C virus. Nature 461:798-801.